There are three other therapies (one a device) which are currently in Phase 3 in PWS. One is Acadia’s candidate, intranasal carbetocin, which I think also has a good chance of Phase 3 success and approval. The trial's primary outcome is in hyperphagia but this drug has previously been demonstrated to also improve anxiousness.
There are several Phase 2 studies ahead of us as well. Some are focused on hyperphagia and others on behaviour and excessive sleepiness.
So there may already be a range of other therapy options if and when NNZ-2591 in PWS comes to market.
PWS Clinical Trials (fpwr.org)
There are three other therapies (one a device) which are...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.34 |
Change
1.140(5.64%) |
Mkt cap ! $2.725B | |||
| Open | High | Low | Value | Volume |
| $20.30 | $21.65 | $20.11 | $14.34M | 673.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 633 | $21.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.34 | 2000 | 2 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.37 |
Change
1.140 ( 5.63 %) |
||||
| Open | High | Low | Volume | ||
| $20.26 | $21.64 | $20.19 | 136487 | ||
| Last updated 15.59pm 15/05/2024 ? | |||||
| NEU (ASX) Chart |